Journal of Ayurveda and Integrative Medicine (Jul 2021)
A study on toxicity and anti-hyperglycemic effects of Abhrak Bhasma in rats
Abstract
Background: Abhrak bhasma (AB) is widely used in the treatment of diabetes mellitus (DM); however, no scientific study is reported till date on its efficacy and safety to prove it's pharmacological effects. Streptozotocin (STZ) is a gulcosamine–nitrosourea complex produced by Streptomyces achromogenes, which particularly induces DNA strand breakage in pancreatic β-cells causing DM. The damage caused by STZ to pancreatic β-cells is coupled with insulin release in the initial stage, subsequently leading to hyperglycemia owing to insulin deficiency. Objective(s): In the present study, the safety and effectiveness of AB was evaluated by in vivo acute and sub-acute toxicity study and STZ-induced hyperglycemic activity in rats. Materials and methods: Acute oral toxicity assessed as per OECD 425 guidelines by employing up-down procedure (UDP), sub-acute toxicity as per OECD-407 guidelines and anti-hyperglycemic activity using STZ method. The anti-hyperglycemic potential of AB in rats (40, 80, and 160 mg/kg body weight (b.w.)) was evaluated by determining the body weight, blood glucose, organ weight, lipid profile, and histo-morphological and histo-pathological investigations. Results: The highest tolerated dose of AB was 2000 mg/kg b.w., and sub-acute toxicity of different AB doses showed no significant variation, when compared with the control. Interestingly, a noteworthy reduction in blood glucose, total cholesterol, and triglycerides levels were observed in AB-treated diabetic rats, along with a considerable increase in body weight, when compared with those noted in the disease control and normal control. Conclusion: Effectiveness of AB as a potential safe and potent candidate for the treatment of diabetes was revealed as compared to the standard drug Metformin by STZ-induced method.
